MA27670A1 - Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique - Google Patents

Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique

Info

Publication number
MA27670A1
MA27670A1 MA28525A MA28525A MA27670A1 MA 27670 A1 MA27670 A1 MA 27670A1 MA 28525 A MA28525 A MA 28525A MA 28525 A MA28525 A MA 28525A MA 27670 A1 MA27670 A1 MA 27670A1
Authority
MA
Morocco
Prior art keywords
fluoroanilino
chloro
methyl
phenylacetic acid
pharmaceutical composition
Prior art date
Application number
MA28525A
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27670(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27670A1 publication Critical patent/MA27670A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a trait à des compositions contenant des suspensions aqueuses d'acide 5-méthyl-2-(2'-chloro-6'-fluoroanilino)phénylacétique, convenant à une administration orale. L'invention concerne également des procédés de production de telles compositions, ainsi que leurs procédés de stabilisation.
MA28525A 2003-03-12 2005-09-30 Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique MA27670A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
MA27670A1 true MA27670A1 (fr) 2005-12-01

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28525A MA27670A1 (fr) 2003-03-12 2005-09-30 Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique

Country Status (29)

Country Link
US (2) US20060094787A1 (fr)
EP (1) EP1603550B1 (fr)
JP (1) JP4580921B2 (fr)
KR (1) KR20050109077A (fr)
CN (1) CN100345536C (fr)
AR (1) AR043536A1 (fr)
AT (1) ATE418332T1 (fr)
AU (1) AU2004218921B2 (fr)
BR (1) BRPI0408270A (fr)
CA (1) CA2518393A1 (fr)
CL (1) CL2004000496A1 (fr)
DE (1) DE602004018622D1 (fr)
EC (1) ECSP055998A (fr)
ES (1) ES2318277T3 (fr)
HR (1) HRP20050787A2 (fr)
IL (1) IL170518A (fr)
IS (1) IS2658B (fr)
MA (1) MA27670A1 (fr)
MX (1) MXPA05009686A (fr)
MY (1) MY139455A (fr)
NO (1) NO20054662L (fr)
NZ (1) NZ542218A (fr)
PE (1) PE20041063A1 (fr)
PT (1) PT1603550E (fr)
RU (1) RU2363462C2 (fr)
TN (1) TNSN05222A1 (fr)
TW (1) TWI327913B (fr)
WO (1) WO2004080451A1 (fr)
ZA (1) ZA200506750B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003929A (es) * 2003-10-08 2006-07-05 Novartis Ag Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino) -fenilacetico.
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
EP2316422A1 (fr) * 2007-11-12 2011-05-04 Novartis AG Compositions pharmaceutiques liquides contenant du valsartan
EP2926810A1 (fr) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations pharmaceutiques liquides orales de loxoprophène
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP4755373A1 (fr) 2016-09-09 2026-06-10 Azurity Pharmaceuticals, Inc. Suspensions et diluants de metronidazole et de baclofene
WO2018237327A1 (fr) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
EP3687501A4 (fr) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AU2003207453A1 (en) * 2002-01-07 2003-07-24 Pharmacia Corp Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
EP1497268A4 (fr) * 2002-04-05 2006-01-18 Nitromed Inc Donneurs de monoxyde d'azote, compositions et procedes d'utilisation, applications correspondantes

Also Published As

Publication number Publication date
US20060094787A1 (en) 2006-05-04
JP2006519811A (ja) 2006-08-31
HK1086492A1 (en) 2006-09-22
DE602004018622D1 (de) 2009-02-05
RU2005131310A (ru) 2006-05-10
KR20050109077A (ko) 2005-11-17
IL170518A (en) 2010-11-30
US20090048344A1 (en) 2009-02-19
WO2004080451A1 (fr) 2004-09-23
CN1756541A (zh) 2006-04-05
CN100345536C (zh) 2007-10-31
AR043536A1 (es) 2005-08-03
TW200505429A (en) 2005-02-16
ATE418332T1 (de) 2009-01-15
ECSP055998A (es) 2006-01-27
EP1603550B1 (fr) 2008-12-24
HRP20050787A2 (en) 2006-12-31
TNSN05222A1 (en) 2007-06-11
PT1603550E (pt) 2009-03-20
NO20054662L (no) 2005-12-05
NO20054662D0 (no) 2005-10-11
MXPA05009686A (es) 2005-10-20
TWI327913B (en) 2010-08-01
NZ542218A (en) 2009-01-31
EP1603550A1 (fr) 2005-12-14
RU2363462C2 (ru) 2009-08-10
JP4580921B2 (ja) 2010-11-17
BRPI0408270A (pt) 2006-03-07
AU2004218921A1 (en) 2004-09-23
CA2518393A1 (fr) 2004-09-23
CL2004000496A1 (es) 2005-01-14
ZA200506750B (en) 2007-02-28
PE20041063A1 (es) 2005-03-07
MY139455A (en) 2009-10-30
IS2658B (is) 2010-08-15
IS8049A (is) 2005-09-28
AU2004218921B2 (en) 2007-05-17
ES2318277T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA29909B1 (fr) Derives de pyridazine
SE0302760D0 (sv) New compounds
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MX2009002220A (es) Sistemas y metodos desinfectantes.
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
MA29480B1 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
CY1106375T1 (el) Χρηση της επιγαστινης για την αντιμετωπιση αλλepγικης ρινιτιδας/επιπεφυκιτιδας
BR0211736A (pt) Formulação para suspensão oral estabilizada
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
MA29554B1 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
NO20062877L (no) Stabile liposomsammensetninger som omfatter lipofile aminholdige farmasoytiske midler
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
NO20073549L (no) Fremgangsmate for fremstilling av organiske forbindelser
MY139455A (en) Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
BRPI0312377A8 (pt) Suspensão aquosa estéril contendo ciclesonida
NO20061045L (no) Imidazolderivater
BR0208504A (pt) Composição farmacêutica estável de pravastatina